266 related articles for article (PubMed ID: 29129093)
1. Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.
Lyons TG; Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):53. PubMed ID: 29129093
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
Schlößer HA; Drebber U; Kloth M; Thelen M; Rothschild SI; Haase S; Garcia-Marquez M; Wennhold K; Berlth F; Urbanski A; Alakus H; Schauss A; Shimabukuro-Vornhagen A; Theurich S; Warnecke-Ebertz U; Stippel DL; Zippelius A; Büttner R; Hallek M; Hölscher AH; Zander T; Mönig SP; von Bergwelt-Baildon M
Oncoimmunology; 2016 May; 5(5):e1100789. PubMed ID: 27467911
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in small cell lung cancer.
Pakkala S; Owonikoko TK
J Thorac Dis; 2018 Feb; 10(Suppl 3):S460-S467. PubMed ID: 29593891
[TBL] [Abstract][Full Text] [Related]
10. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for immunotherapy in melanoma.
Teixidó C; González-Cao M; Karachaliou N; Rosell R
Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of immune checkpoint inhibitors.
Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
14. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 and its inhibitors in esophageal cancer: efficacy of therapy and potential mechanisms of adverse events.
Tian C; Wang X; Zhang S
Am J Cancer Res; 2023; 13(7):3140-3156. PubMed ID: 37559996
[TBL] [Abstract][Full Text] [Related]
19. Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor.
Dhupar R; Van Der Kraak L; Pennathur A; Schuchert MJ; Nason KS; Luketich JD; Lotze MT
Ann Thorac Surg; 2017 Apr; 103(4):1340-1349. PubMed ID: 28359471
[TBL] [Abstract][Full Text] [Related]
20. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.
Momtaz P; Postow MA
Pharmgenomics Pers Med; 2014; 7():357-65. PubMed ID: 25484597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]